Dopaminergic and cholinergic involvement in the inhibitory effect of dexamethasone on the TSH response to TRH.

What Was Tested

Researchers studied Dexamethasone and Glucocorticoids in this randomized controlled trial publication.

The researchers measured the TSH response to TRH and serum-free T4 and T3 levels.

Who Took Part

The abstract describes 18 men taking part.

PubMed indexes the participants as adults, men only.

Subjects from group 3 were tested with TRH after placebo, dex, or dex plus pyridostigmine plus MCP.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Dexamethasone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Dexamethasone could be set against what happens without it.

The researchers used the antidopaminergic agent metoclopramide (MCP) and the acetylcholinesterase inhibitor pyridostigmine, which enhances acetylcholine and thus inhibits hypothalamic somatostatin release.

What Was Measured

The researchers measured the TSH response to TRH and serum-free T4 and T3 levels.

The subject headings attached to it are Choline, Cholinesterase Inhibitors, Dexamethasone, Dopamine, Dopamine Antagonists, Glucocorticoids and Hypothalamus.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Dexamethasone and Glucocorticoids in 18 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Journal of investigative medicine : the official publication of the American Federation for Clinical Research), a journal based in England.

More context: all human trials.